LWCFA
SRPT icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7
Closed -$416 – 558
2025
Q1 		$416 Hold
7
– – ﹤0.01% 547
2024
Q4 		$818 Sell
7
-19
-73% -$2.33K ﹤0.01% 537
2024
Q3 		$3.43K Buy
+26
New +$3.59K ﹤0.01% 536

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's SRPT Position: Q2 2025 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 7 shares — an estimated $416 sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in SRPT in Q3 2024 and held it in 3 quarters. The position peaked at $3.43K in Q3 2024. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 7 Sarepta Therapeutics shares in Q2 2025, an estimated $416.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Sarepta Therapeutics in Q3 2024 and held it in 3 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Sarepta Therapeutics position peaked at $3.43K in Q3 2024.
  • 363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.